Neurona banks $23.5M to develop circuit-repairing therapies

South San Francisco startup Neurona Therapeutics raised a $23.5 million A round to support its work on a cell therapy approach to neurological disease. The round, led by the Column Group, will bankroll Neurona's efforts to develop cell-based treatments that can repair damaged neural circuits by implanting particular types of neurons. The nascent company was founded by neuroscientists and stem cell researchers from the University of California, San Francisco and Column partner Tim Kutzkey has stepped in to lead as CEO. Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.